Medicare Chief: Engage With Us On Payment Experiment
This article was originally published in Scrip
Executive Summary
Centers for Medicare & Medicaid Services (CMS) acting administrator Andy Slavitt entered the lion's den on March 9 and faced about 300 hundred drug company executives and other health care stakeholders at a meeting in Washington the day after releasing a controversial proposal to overhaul the way the government pays for outpatient prescription medicines, which had some industry leaders up in arms before it was even officially revealed.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.